Rationale: High-density lipoprotein (HDL) cholesterol elevation via cholesteryl ester transfer protein (CETP) inhibition represents a novel therapy for atherosclerosis, which may also have relevance for type 2 diabetes.
INTRODUCTION
Recent clinical studies indicate that high-density lipoprotein (HDL) cholesterol exerts beneficial actions beyond cardiovascular protection, which may extend to type 2 diabetes. We have previously shown that reconstituted HDL (rHDL) infusion in individuals with type 2 diabetes can increase plasma insulin and lower circulating glucose. 1 The actions of HDL and its major protein, apolipoprotein AI (apoAI), to enhance insulin secretion [1] [2] [3] [4] [5] and to stimulate glucose uptake in skeletal muscle 1, 6 suggest that HDL-raising agents may have efficacy in improving β-cell function and glucose homeostasis. These DOI: 10.1161/CIRCRESAHA.113.300689 3 findings raise the possibility that HDL-elevating agents currently under development for treatment of atherosclerotic coronary disease may have therapeutic relevance for the management of type 2 diabetes. 7, 8 Pancreatic β-cell dysfunction is a hallmark of late stage type 2 diabetes. 9 Underlying mechanisms include lipid accumulation with subsequent inflammation, 10 oxidative stress 11 including lipid peroxidation 12 and endoplasmic reticulum stress. 13 HDL may protect against β-cell dysfunction and increase glucose-stimulated insulin secretion (GSIS) via cellular cholesterol removal 2, 4, [14] [15] [16] and/or direct signaling actions. 3 Evidence for the emerging role of HDL in glucose metabolism has been recently reviewed. [17] [18] [19] Previous cellular, animal and human studies suggest that raising plasma HDL cholesterol may modulate insulin secretion. 5, [20] [21] [22] Cholesteryl ester transfer protein (CETP) inhibition raises plasma HDL cholesterol via a reduction in the transfer of neutral lipids (triglycerides and cholesteryl esters) between HDL and triglyceride-rich lipoprotein particles. The efficacy of this strategy to improve cardiovascular outcomes has not yet been determined and there is controversy regarding whether CETP inhibition might produce a dysfunctional form of HDL cholesterol, which is less efficient at promoting reverse cholesterol transport than native HDL. 23 This controversy has arisen in part due to the early termination of two CETP inhibitor trials due to adverse events in the case of torcetrapib 24 and more recently, lack of efficacy with dalcetrapib. 25 Despite this, the CETP inhibitor (CETPi) class of HDL-elevating agents remains the most advanced therapeutic strategy for long-term HDL elevation with two agents currently in late phase clinical development (Phase III) for the management of coronary artery disease. 8, 26 While the primary focus of CETP inhibition has been on cardiovascular outcomes, a sub-study of the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial reported favorable effects on glucose metabolism in patients with type 2 diabetes when treated with torcetrapib. 20 While the mechanisms leading to improved glycemic control were not investigated, we hypothesize that enhanced β-cell function is a likely contributor.
The current study investigated whether raising HDL cholesterol via CETP inhibition can promote insulin secretion in humans. In a randomized, placebo-controlled parallel design clinical trial of a 14 day CETPi intervention, plasma indices of glycemic control were measured. Subsequent ex vivo analyses of MIN6N8 pancreatic -cell function were performed, including insulin secretion and cholesterol efflux following treatment with plasma from CETPi vs placebo-treated individuals.
METHODS

Human CETPi trial.
To examine the effects of HDL-elevation on insulin secretory function, a randomized, placebo-controlled parallel design clinical trial was performed. The CETPi intervention period was 14 days. Twenty-five healthy males (n=10 CETPi, n=15 placebo) gave written informed consent to participate in the study, which was approved by the Ethics Committee of the Two Basels (Switzerland). A fasting blood sample was taken prior to a standardized breakfast (10.4g fat, 18.5g protein, ≤80g carbohydrate; total energy 1989kJ) and a 15min postprandial blood sample was also taken immediately before a once daily oral dose (420mg) of CETPi (RG7232, PCT #WO2007090748) or matching placebo.
Plasma analyses.
Fasting and 15min postprandial blood was collected on the first (day 1) and last day (day 14) of the study and the plasma was stored at -80ºC until analysis. Total, HDL and low-density lipoprotein (LDL) cholesterol and triglyceride concentrations were measured in fasting plasma samples on a Roche Modular System using either enzymatic methods or direct homogeneous assays (Modular Analytics D2400 module, Roche Diagnostics, IN). Apolipoprotein AI and apoAII were measured using an automated nephelometer (Dade Behring BNII, Siemens Healthcare Diagnostics, IL) in fasting plasma after depletion of apoB-containing lipoproteins by a precipitation method using 0.1% 1.1 dextralip/MgCl 2 (SigmaAldrich, Sydney, NSW, Australia). HDL-associated free cholesterol and triglyceride concentration were measured using an enzymatic colorimetric assay on a chemistry immuno-analyzer (Olympus AU 2700, Olympus, PA). Human ELISA kits were used to measure plasma insulin (EZHIASF-14K, Millipore Australia, Kilsyth, VIC, Australia), gastric inhibitory polypeptide (GIP; EZHGIP-54K, Millipore Australia) and glucagon-like peptide 1 (GLP-1; EZGLP1T-36K, Millipore Australia) concentrations in postprandial samples taken on day 1 and day 14. Postprandial C-peptide, fasting and postprandial glucose concentrations were all measured on an automated analyzer (Architect ci16200, Abbott Diagnostics, IL). To evaluate the efficacy of the CETP inhibitor, plasma CETP activity was measured using a homogeneous, fluorometric assay kit (Roar Ex-vivo CETP Activity Assay, Roar Biomedical, NY).
Plasma preparation for ex vivo analyses.
To study the effects of HDL, plasma was prepared for ex vivo studies by precipitating out apoBcontaining lipoproteins via incubation with 0.1% 1.1 dextralip/MgCl 2 (Sigma-Aldrich) followed by centrifugation at 20,817 x g for 30min to remove very low-density lipoprotein (VLDL) and LDL particles.
1 Supernatant was dialyzed against PBS/EDTA using tube-o-dialyzers (G biosciences; St Louis, MO) to remove all molecules less than 15,000Da, including insulin and glucose and subsequently referred to as CETPi-plasma or placebo-plasma.
LDL oxidation.
LDL (density = 1.019-1.063g/ml) was isolated from the plasma of healthy individuals by sequential ultracentrifugation, as previously described. 1 The lipoproteins were then dialyzed overnight against PBS/EDTA at 4ºC. For the ex vivo cholesterol efflux and insulin secretion assays, LDL was oxidized by incubating 1.5mg/ml LDL protein with 10μmol/L CuSO 4 for 110min at RT in the dark. Oxidation was stopped by adding EDTA at 60μmol/L at RT. The extent of lipoperoxide formation was quantitated by measuring thiobarbituric acid reactive substances (TBARS) in a validated assay. 27 Duplicate standards and oxLDL samples were mixed with two volumes of ice-cold 10% (w/v) trichloroacetic acid (SigmaAldrich) and 3 volumes of 1% (w/v) thiobarbituric acid (Sigma-Aldrich) and incubated at 95ºC for 30min. Samples were centrifuged (16,200 x g, 5min) at RT before 200μl of the supernatant was transferred to a 96-well plate and absorbance measured at 532nm using a Bio-Rad plate reader (Bio-Rad Laboratories, Gladesville, NSW, Australia).
An 8-point calibration curve was prepared using 1,1,3,3-tetramethoxypropane (0-100μM) and results expressed as nmol of malondialdehyde (MDA) equivalents/mg LDL protein. The oxLDL used for the ex vivo assays was not fully oxidized as indicated by the TBARS assay (27nmol MDA equivalents/mg LDL protein) and compared to previous studies. 28, 29 Ex vivo insulin secretion from MIN6N8 pancreatic β-cells. Insulin secretion was assessed in murine MIN6N8 pancreatic β-cells provided by Prof Jun-ichi Miyagaki (Osaka University, Osaka, Japan) 30 using a modified protocol. 31 MIN6N8 pancreatic β-cells were grown in 5mmol/L glucose DMEM supplemented with 10% FCS plus 1% penicillin/streptomycin (37ºC, 95% O 2 /5% CO 2 ) to sub-confluence then placed in 5mmol/L glucose DMEM with 2% FCS. Cells were incubated with 3.5% CETPi-plasma, placebo-plasma, lipoprotein-free plasma, HDL (1.8mmol/L)-spiked plasma, DMSO or 100ng/ml CETPi for 72h along with oxidized low-density lipoprotein (oxLDL) (50μg/ml) to simulate the pathophysiology of type 2 diabetes. 2, 32, 33 This is a well-validated technique to cholesterol-load cells 28, 34 and an appropriate model to examine whether plasma HDL elevation in individuals treated with the CETPi increased GSIS and cholesterol efflux. Treatment of MIN6N8 pancreatic β-cells with oxLDL (50μg/ml) had no adverse effect on cell morphology, culture confluence or key apoptotic (Bax, Casp3, Bclx, Ptpn2, Bim & Puma) or anti-apoptotic (Bcl2) gene markers involved in different cell death pathways (data not shown). Basal insulin secretion was determined after incubation in low (2.8mmol/L) glucose Krebs-Ringer Bicarbonate buffer (KRBB) for 30min whereas first phase (20min) and second phase (40min) GSIS were measured in response to separate 20mmol/L glucose boluses. Cells were lyzed in water and sonicated for 15min at 4ºC to determine intracellular insulin. Secreted and intracellular insulin were measured using a rat/mouse insulin ELISA kit (EZRMI-13K, Millipore Australia). Total insulin was calculated as the sum of insulin secreted during the basal, first and second phases, plus intracellular insulin at the end of the experiment. Insulin secretion data are expressed as either a percentage change in absolute insulin secretion at day 14 compared to day 1 ( Figure 1 ) or insulin secretion rat (ng/ml/hr; Table 4 ).
Ex vivo cholesterol efflux from MIN6N8 pancreatic β-cells.
Cholesterol efflux assays were performed using a modified protocol as described previously.
35 MIN6N8 pancreatic β-cells were grown in 5mmol/L glucose DMEM with 10% FCS to sub-confluence then labelled with [1α,2α(n)- 3 H]cholesterol ([ 3 H]cholesterol 1μCi/ml; GE Healthcare, UK) in ethanol vehicle (<0.4%) and oxLDL (50μg/ml) to facilitate cholesterol loading for 48h at 37ºC (95% O 2 /5% CO 2 ). Cells were washed with PBS then treated with the liver-X-receptor (LXR) agonist (TO-901317, 1μmol/L) to stimulate ABCA1 expression in serum-free DMEM for 18h. Human HDL (10, 25 and 50μg/ml) and apoAI (20μg/ml) were used as positive controls. Experimental treatments included CETPi-plasma (n=5) and placebo-plasma (n=5) collected on day 1 and day 14 of the treatment period, at a concentration of 3.5% v/v. This plasma dilution was selected on the basis of preliminary experiments showing that 3.5% plasma elicited cholesterol efflux of a magnitude similar to 50μg/mL of HDL; a concentration in the midrange of the cholesterol efflux dose-response curve. This was the same dilution used in the insulin secretion experiments. [ 3 H]cholesterol was measured in quadruplicate samples after a 3h cholesterol efflux assay into serum-free DMEM, which was centrifuged at 15,700 x g for 5min. Cells were lyzed in 0.1M NaOH/0.1% SDS and assayed for protein content. 
Statistical analysis.
Data were analyzed using unpaired two-tailed Student's t-tests when only two experimental groups were compared and for more than two groups by one-way ANOVA or repeated measures one-way ANOVA as appropriate and where significant (p<0.05), comparison of individual means was performed with a Tukey HSD test. Correlation analysis was performed using the Pearson coefficient. Results are expressed as mean  SD. All analyses were conducted using SPSS (v16) and Sigmastat (v3.5). p<0.05 was deemed significant.
RESULTS
Effect of CETPi on human plasma parameters.
There were no differences in age (CETPi: 329 vs placebo: 359 years) or body mass index (CETPi: 23.01.0 vs placebo: 24.50.5kg/m 2 ) between groups. There were also no pre-dosing differences in CETP activity at baseline between the treatment groups ( Table 1 ). The efficacy of the CETPi was confirmed with more than 80% inhibition of plasma CETP activity achieved for up to 12h post-dose on both day 1 and day 14 of the treatment period (Table 1) Table 2 ). The increase in postprandial insulin (+75%) after the 14 day CETPi intervention was greater than with placebo (+42%) treatment (p<0.05, Figure 1A ). The change in plasma C-peptide concentration mirrored that of insulin, though failed to reach statistical significance (p=0.08; Figure 1B ). Despite the increase in insulin, there was no difference between groups in fasting or postprandial glucose measured 15min after a standardized breakfast (Table 2) . Importantly, there was no effect of the CETPi on the change in postprandial plasma GIP ( Figure 1C ) or GLP-1 ( Figure 1D) concentrations.
Over the 14 day intervention period there was a strong correlation between the change in plasma HDL cholesterol and apoAI (r=0.90, p<0.001). The change in both plasma HDL and apoAI correlated significantly with the change in postprandial insulin (HDL r=0.53, p<0.01; apoAI r=0.41, p<0.05, Table  3 ).
Effect of CETPi-plasma on insulin secretion from mouse pancreatic β-cells.
There was no difference between groups (CETPi-plasma vs placebo-plasma) in the absolute rate (Table 4) or percentage change (day 14 -day 1) in basal insulin secretion (Figure 2A ). Glucosestimulated insulin secretion was higher after treatment with the CETPi-plasma. The percentage change (from day 1) in both first phase (+41±91%) and second phase (+32±49%) GSIS was greater after exposure to CETPi-plasma compared with placebo-plasma (p<0.05, Figure 2B & C). Additionally, when the data were expressed as a rate, the absolute change (day14 -day1) in first phase (p=0.05, Table 4 ) and second phase (p<0.05, Table 4 ) GSIS were higher after treatment with CETPi-plasma compared with placebo-plasma. The change in total insulin remaining in lyzed pancreatic β-cells after 14 days of treatment was correspondingly lower after incubation with CETPi-plasma compared with placebo-plasma (p<0.05, Table 4 ). The change in GSIS between day 1 and 14 in the placebo group was not significant. There was no significant correlation between the change in either plasma HDL or apoAI and the change in first or second phase GSIS (Table 3) .
To test whether HDL can stimulate insulin release, MIN6N8 pancreatic β-cells were treated with lipoprotein-free plasma and plasma spiked with human HDL at a concentration (1.8mmol/L) equivalent to that achieved after CETPi treatment in study participants. The data show a 7.6±0.6-fold increase in first phase (n=6, p<0.0001) and a 2.7±0.3-fold increase in second phase insulin secretion (n=6, p<0.001) in the HDL-spiked plasma relative to lipoprotein free plasma.
Importantly, direct incubation with the CETPi drug at concentrations equivalent to those found in plasma following the 14 day treatment period resulted in no change in either basal insulin secretion or first and second phase GSIS (Table 5 ). There was also no change in total insulin remaining in the lyzed cells following direct incubation with the drug (Table 5) .
Effect of CETPi-plasma on cholesterol efflux from mouse pancreatic β-cells.
Incubation of cholesterol-loaded MIN6N8 pancreatic β-cells with human HDL stimulated net cholesterol efflux with a linear dose-dependent relationship ( Figure 3A ). ApoAI also acted as a cholesterol acceptor, resulting in a greater than two-fold increase in cholesterol efflux even at a relatively low concentration (20μg/ml) ( Figure 3A ). There was a nine-fold increase in cholesterol efflux at the highest dose of HDL (50μg/ml) when compared to control with no acceptor ( Figure 3A) , which is equivalent to the magnitude of efflux achieved with 3.5% plasma ( Figure 3B ). The absolute change (day 14 -day 1) in cholesterol efflux to CETPi-plasma (1.23±0.39%) was 12-fold greater than for placeboplasma (0.10±0.13%, p<0.001, Figure 3B ). Both the change in plasma HDL cholesterol and apoAI concentrations correlated strongly with the change in cholesterol efflux (r=0.78 and 0.70 respectively, p<0.05, Table 3 ).
DISCUSSION
We report here for the first time that CETP inhibition in healthy humans increases postprandial insulin and ex vivo GSIS. These observations provide clinical context to previous work linking HDL with insulin secretion in cell and animal models, 1, 3, 5 as well as human studies of both a single HDL infusion 1 as well as HDL elevation over 6 months. 20 These data are consistent with the hypothesis that HDL elevation via CETP inhibition may improve β-cell function and postprandial insulin secretion in individuals with type 2 diabetes to mitigate harmful postprandial glycemic excursions. 36, 38, 39 This possibility requires testing in large CETPi clinical trials involving patients with type 2 diabetes.
Following CETP inhibition for 14 days, postprandial insulin and C-peptide increased more than two-fold when compared to placebo. Furthermore, the change in plasma HDL cholesterol and apoAI positively correlated with the change in postprandial insulin over that same treatment period. The postprandial sample was taken 15 minutes after a standardized meal when glucose concentrations in the placebo and CETPi-treated groups were equivalent. This suggests that for a given postprandial rise in glucose (2-3mmol/L in this study) in these healthy individuals, CETPi treatment resulted in a greater increase in plasma insulin. Importantly, this was not due to an effect on the major incretins, GIP and GLP-1.
It is anticipated that the higher circulating insulin would enhance postprandial glucose clearance after CETPi-induced HDL elevation, though blood was not sampled at later time points. Increased postprandial insulin could benefit those with established type 2 diabetes, who typically have high fasting insulin, but impaired β-cell sensitivity and insulin secretory response to a glucose load. This latter effect generally manifests itself as a blunted postprandial first phase insulin response resulting in a greater plasma glucose excursion and delayed post-meal recovery. 37 CETP inhibition thus has the potential to improve postprandial glycemic control without disturbing the incretin response.
In a previous study we reported that HDL at a concentration of 50μg/ml, which equates to an apoAI concentration of approximately 40μg/ml, rescues oxLDL-induced reductions in MIN6N8 pancreatic β-cell GSIS, but has no effect alone. 1 The current study develops a therapeutic context, showing that apoB-depleted, dialyzed plasma taken from CETPi-treated (vs placebo-treated) individuals, increases first and second phase GSIS from MIN6N8 pancreatic β-cells pre-treated with oxLDL. Importantly, this effect was shown to be specific to glucose-stimulated insulin responses as basal insulin secretion was not altered.
The insulin secretory effect is most likely due to the HDL elevation induced by the CETPi since there was no direct effect of the CETPi on insulin secretion and lipoprotein free plasma spiked with HDL at the concentration (1.8mmol/L) equivalent to that achieved after CETPi treatment in study participants stimulated significant insulin secretion. HDL-elevating therapies, such as CETP inhibition may therefore augment β-cell sensitivity to glucose, resulting in enhanced GSIS and improved glucose tolerance without exacerbating the characteristic fasting hyperinsulinemia observed in those individuals with type 2 diabetes.
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While plasma HDL cholesterol and apoAI positively correlated with the change in postprandial insulin, the weaker relationships between the change in first and second phase GSIS and plasma HDL/apoA-I would be anticipated given the more complex and variable nature of the insulin secretion assay, compared with direct measures of plasma insulin. Specifically, the insulin secretion assay includes variables related to the MIN6 cell culture including variability in cell density, culture conditions, cell viability and response to oxLDL treatment. In addition, the plasma preparation used to stimulate insulin secretion involves multiple preparation steps including ultracentrifugation, dialysis and dilution, all of which could introduce further variability.
Mechanisms.
There are a number of mechanisms that may explain the observed increase in GSIS from MIN6N8 pancreatic β-cells after incubation with plasma from individuals treated with the CETPi (CETPi-plasma). Given the higher plasma HDL cholesterol concentrations after CETP inhibition and the important role of HDL and apoAI in reverse cholesterol transport, a reduction in β-cell lipid content is one possible explanation. Our results show functional cholesterol efflux from MIN6N8 pancreatic β-cells to human plasma. Most importantly, efflux to CETPi-plasma was increased over the 14 day treatment period with no change in efflux to placebo-plasma. Interestingly, the change in plasma HDL cholesterol and apoAI across the treatment period strongly correlated with the change in ex vivo cholesterol efflux. Consistent with previous literature linking HDL to insulin secretion from β-cells, 2, 4, 14-16 our observations suggest that CETP inhibition may modulate insulin secretion via changes in net cholesterol efflux. Cholesterol accumulation has been identified as an important precursor to β-cell dysfunction and failure, particularly in the context of type 2 diabetes. 3, 16, 40, 41 These pathologies can be largely rescued in vitro by reducing β-cell cholesterol content with statins or methyl-β-cyclodextrin. 41, 42 Combined, these data suggest that abnormalities in cholesterol homeostasis may contribute to impaired β-cell function typical of type 2 diabetes and that this may be rescued by CETP inhibition.
It is also possible that HDL and apoAI may increase insulin secretory capacity via direct signaling actions independent of lipid removal. Using apoAI at a concentration approximately 20-fold higher (864μg/ml) than our earlier study, 1 Fryirs et al. reported an increase in basal insulin secretion and GSIS from mouse pancreatic β-cells, in the absence of cholesterol loading with oxLDL. 3 This effect was observed without depletion of intracellular cholesterol, although functional cholesterol efflux was not measured. These results suggest that at these higher doses, apoAI may act as an insulin secretagogue, perhaps acting via direct signaling pathways linked to the HDL transporters, ATP binding cassette transporter A1 (ABCA1) and ABCG1.
3, 14, 15, 17 A critical role for ABCA1 and cellular cholesterol has recently been reported for regulating insulin granule fusion events in pancreatic -cells. 43 The facilitative role of ABCA1 in β-cell insulin secretion, whether via cholesterol removal or direct signaling, is supported by the observation that insulin secretory response is defective in mice with a β-cell specific deletion of the ABCA1 transporter. This is also true for patients with loss of function mutations in the ABCA1 gene with low circulating HDL.
14, 40, 44 Furthermore, the absence of both ABCA1 and ABCG1 induces greater defects in β-cell function than deficiency of either transporter individually, suggesting that these transporters provide important and complementary contributions to β-cell function by maintaining islet cholesterol homeostasis in vivo. 45 At a cellular level, cholesterol content can affect membrane fluidity and permeability, 46 as well as cell signaling via membrane microdomains or sterol regulatory element-binding proteins.
3, 47
Clinical context.
While no large clinical trials have directly examined the long-term effects of HDL-raising agents on postprandial glycemic control, circumstantial evidence of a beneficial effect is emerging. Post-hoc analyses following the ILLUMINATE trial showed that patients treated with torcetrapib in conjunction with atorvastatin had lower fasting glucose (-0.34mmol/L) and HbA 1c (-0.33%) at 3 months compared with those on the statin alone. 20 This was observed in addition to conventional management of type 2 diabetes with hypoglycemic agents and despite lower fasting insulin in the CETPi-treated group. 20 The improved glucose control in these patients may be due to a combination of factors including increased circulating HDL cholesterol and apoAI with a concomitant reduction in LDL cholesterol, improvement in β-cell function or enhanced insulin sensitivity and skeletal muscle glucose uptake, as we and others have shown previously. 1, 6 As glycemic control was not the primary endpoint in the ILLUMINATE trial, no postprandial glucose or insulin data were collected. Current large clinical trials examining the effects of potent second generation CETP inhibitors, 48 including anacetrapib, 7, 8 and evacetrapib 26 on cardiovascular events provide an ideal opportunity to study the effects of HDL elevation on glucose homeostasis in more detail.
Limitations.
Ideally, a more comprehensive time-course study of CETPi actions on circulating insulin and glucose would have been undertaken. In vivo assessment of insulin secretion would also have been informative in these individuals. However, this clinical trial was not designed to assess these parameters and the necessary investigations were either not performed or the plasma was not available. Despite these shortcomings, the current study provides evidence that HDL elevation via CETP inhibition can influence postprandial insulin responses and therefore supports a rationale for more detailed investigations.
Conclusion.
The current study links HDL cholesterol to insulin secretion via novel actions of CETP inhibition in raising postprandial insulin in healthy individuals in association with enhanced ex vivo cholesterol efflux and GSIS from MIN6N8 pancreatic β-cells. These data provide clinical context for investigation of HDL-raising agents as potential therapies for the management of type 2 diabetes. Of particular interest is the possibility that CETP inhibition, via effects on β-cell insulin secretion, may reduce harmful postprandial glycemic excursions and associated vascular complications. ACKNOWLEDGMENTS F. Hoffman La Roche (Basel, Switzerland) provided plasma from their clinical trial using the CETPi (RG7232, Patent Cooperation Treaty #WO2007090748), but provided no funding for the study. 
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Novelty and Significance
What Is Known?
 Protective effects of high-density lipoprotein (HDL) against cardiovascular disease risk have been linked with increased cholesterol efflux and reverse cholesterol transport.
 HDL has more recently been shown to modulate insulin secretion and stimulate glucose uptake into skeletal muscle.
 Cholesteryl ester transfer protein (CETP) inhibitors are HDL-raising agents currently in phase 3 clinical trials, but the effects of these agents on insulin secretion have not been examined.
What New Information Does This Article Contribute?
 Raising plasma HDL cholesterol by 48% and apoAI by 24% via CETP inhibitor therapy for 14 days increases postprandial plasma insulin concentration, in comparison withplacebo treatment.
 Mouse pancreatic β-cells incubated with plasma from individuals treated with a CETP inhibitor exhibited an increase in both first and second phase glucose-stimulated insulin secretion and cholesterol efflux, with no effect on basal insulin secretion.
 The effects of CETP inhibitors on glucose-stimulated insulin secretion are likely mediated by HDL elevation.
HDL-raising agents are currently being tested for efficacy in reducing the risk of atherosclerotic cardiovascular disease; however, they may be effective also in the management of type 2 diabetes, which is commonly associated with dyslipidemia. The use of one CETP inhibitor is associated with improved glycemic control in patients with type 2 diabetes; but effects on insulin secretion were not examined. The current study shows that in healthy adults HDL elevation via CETP inhibition increases postprandial plasma insulin concentration in healthy individuals and that plasma from these individuals can increase glucose-stimulated insulin secretion and cholesterol efflux from mouse pancreatic β-cells. Furthermore, the elevations in plasma HDL cholesterol and apoAI positively correlated with the change in postprandial plasma insulin. These observations provide clinical therapeutic context to previous work linking HDL with insulin secretion in cell culture and animal models, as well as human studies of both single HDL infusion and longer-term HDL elevation over months. Raising HDL via CETP inhibition may thus improve β-cell function and postprandial insulin secretion in individuals with type 2 diabetes to minimise harmful postprandial glycemic excursions.
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